CTSO
Cytosorbents Corporation
CTSO offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
UNH
UnitedHealth Group Incorporated
UNH has the edge over CTSO overall, supported by lower modeled downside and stronger modeled upside.
CTSO Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Unavailable |
CTSO's revenue is currently stable, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
CTSO PE Valuation
CTSO has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
CTSO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
CTSO has the edge over UNH on the outlook, with more favorable revenue expectations.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
CTSO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$5.80 | -$2.40 |
| Q1 2026 | -$3.80 | +$1.80 |
| Q4 2025 | -$2.60 | +$5.00 |
| Q3 2025 | -$3.60 | +$3.60 |
| Q2 2025 | -$3.40 | +$7.20 |
| Q1 2025 | -$5.60 | +$6.20 |
| Q4 2024 | -$7.60 | +$5.20 |
| Q3 2024 | -$7.20 | +$3.60 |
CTSO is still losing money, but far less than before: $5.80 per share over the past year, against $18.40 at its worst in late 2022.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over CTSO on earnings quality, reporting a profit while its opponent remains loss making.
CTSO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $9.6M | +0.2% |
| Q1 2026 | $8.9M | +1.6% |
| Q4 2025 | $9.2M | +42% |
| Q3 2025 | $9.5M | +1% |
| Q2 2025 | $9.6M | -2.8% |
| Q1 2025 | $8.7M | -11% |
| Q4 2024 | $6.5M | -25% |
| Q3 2024 | $9.4M | +6.6% |
CTSO's revenue has grown year over year for four quarters in a row: $10M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -27% | +10 points |
| Q1 2026 | -34% | +10 points |
| Q4 2025 | -47% | +15 points |
| Q3 2025 | -30% | +17 points |
| Q2 2025 | -38% | -3 points |
| Q1 2025 | -45% | +5.8 points |
| Q4 2024 | -62% | +47 points |
| Q3 2024 | -47% | +37 points |
CTSO's operating margin was −27% last quarter, up 10 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over CTSO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over CTSO on profitability, with a higher operating margin.
CTSO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$597K | +$949.9K |
| Q1 2026 | -$1.2M | +$2.3M |
| Q3 2025 | -$2.6M | -$132.8K |
| Q2 2025 | -$1.5M | +$3.2M |
| Q1 2025 | -$3.5M | +$1.4M |
| Q3 2024 | -$2.5M | +$2.9M |
| Q2 2024 | -$4.8M | +$1.9M |
| Q1 2024 | -$4.9M | -$1.3M |
CTSO has burned cash in almost every quarter: −$9M over the past year, against −$12M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over CTSO on cash generation, producing positive trailing cash flow while its opponent burns cash.
CTSO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +3.4K shares |
| 1 year | -6.5% | -218K shares |
| 3 years | +43% | +940K shares |
| 5 years | +45% | +974K shares |
| Available history | +94% | +1.5M shares |
CTSO has the edge over UNH on shareholder dilution, with a more favorable share count trend.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has 902M diluted shares, down 0.7% from a year ago, with $5B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
CTSO Net Leverage
CTSO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
CTSO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.9 | Neutral |
| Stochastic | 31.3 | Neutral |
CTSO's weekly RSI is 40 (neutral) and its Stochastic is 31 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
CTSO PE vs Healthcare Sector
CTSO has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
CTSO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.54 | 18% above |
| 20 week MA | $6.09 | 12% below |
| 50 week MA | $9.78 | 45% below |
| 100 week MA | $14.6 | 63% below |
| 200 week MA | $25.4 | 79% below |
CTSO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 79% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over CTSO on trend strength, trading above more of its moving averages.
CTSO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $76.6 | $166.2 | +117% |
| 2021 | $166.2 | $89.0 | -46% |
| 2022 | $89.0 | $28.0 | -69% |
| 2023 | $28.0 | $22.2 | -21% |
| 2024 | $22.2 | $18.8 | -15% |
| 2025 | $18.8 | $13.6 | -28% |
| 2026 YTD | $13.6 | $5.37 | -61% |
CTSO has finished five years in a row lower, and it's down 61% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over CTSO on returns for 2026, with the stronger performance.